Cipla has received final approval from the US FDA to market tenofovir disoproxil fumarate tablets 300mg, a generic version of Gilead Sciences’ Viread tablets, 300mg.
Cipla’s tenofovir disoproxil fumarate tablets, 300mg, are AB-rated generic equivalents of Gilead Sciences’ Viread tablets, 300mg, and are indicated in combination with other antiretroviral (ARV) agents for the treatment of HIV-1 infection in adults and paediatric patients 12 years of age and older. Cipla is excited to add this important antiretroviral product to its growing portfolio of ARVs in the US.
The product will be available for commercial shipment in the US immediately. Viread tablets, 300mg, had US sales of approximately $725 million for the 12-month period ending November 2017, as reported by IMS Health.
Whilst delivering a long-term sustainable business, Cipla recognises its duty to provide affordable medicines. Cipla's emphasis on access for patients was recognised globally for the pioneering role played in HIV/AIDS treatment as the first pharmaceutical company to provide a triple combination anti-retroviral (ARV) in Africa at less than a dollar a day and thereby treating many millions of patients since 2001. Cipla's research and development focuses on developing innovative products and drug delivery systems.
Cipla gets us fda approval, market generic viread tablets
.jpg)